Compare Amylx Pharmaceuticals Inc (AMLX) vs American Water Works Company Inc (AWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs American Water Works Company Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.62 (market cap $2.53B), while American Water Works Company Inc trades at $135.76 (market cap $26.92B). The key difference: American Water Works Company Inc is far larger — about 10.6× Amylx Pharmaceuticals Inc's market cap, and American Water Works Company Inc pays a 2.64% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | AWK | |
|---|---|---|
Market Cap | $2.53B | $26.92B |
Sector | Health | Utilities |
52-Week High | $24.19 | $146.20 |
52-Week Low | $7.82 | $121.13 |
Enterprise Value | $2.28B | $42.78B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
AWK trades at $135.31, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.61, beating estimates, while Q1 and Q4 2025 missed. Revenue grew to $5.14B in 2025 with a 21.35% net margin. Analyst consensus is mixed with 14 Buy, 14 Hold, and 2 Sell ratings, targeting $139.83. Recent news highlights operational excellence awards and customer base expansion through acquisitions.
Outlook remains stable with consistent dividend payments and guided EPS growth. Risks include rising debt levels and regulatory pressures. The stock offers steady income and moderate growth potential, but investors should monitor execution on earnings targets and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
